Call them what you will: change makers, thought leaders, people who get stuff done. This is the Science|Business guide to those with the most influence over the size and shape of the EU’s next research programme
The Estonian genome project will provide personal feedback on the genetic information of a third of the population, laying the foundations for personalised medicine
At the Euroscience Open Forum conference, a Bulgarian medical start-up demonstrates the potential - and the challenges - of getting health systems to focus on preventing disease, rather than responding when it strikes
Liquid biopsies can help to diagnose cancer in its early stages, and assist clinicians in monitoring the impact of treatment at any point. IMI's CANCER-ID project has validated a series of tests for cancer cells to help develop more effective methods of diagnosis and more personalised treatments for lung and breast cancer - two of the most frequent malignancies in Europe.
‘Radical collaboration’ where multinational companies work together and share data instead of keeping it secret is helping to change the model of the pharmaceutical industry and solve problems more quickly, according to Carlos Moedas, the EU’s commissioner for research, science and innovation, speaking at an IMI 10th anniversary event in Brussels on 27 June.
The UK decision to leave the EU cuts at science’s core ethos of openness. As exit negotiations lurch along, researchers from across Europe are yet to spot a bright side to losing such an important science partner
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.